<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36373">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633033</url>
  </required_header>
  <id_info>
    <org_study_id>MNK14130050</org_study_id>
    <nct_id>NCT02633033</nct_id>
  </id_info>
  <brief_title>Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse</brief_title>
  <official_title>A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study aims to characterize the patient population and describe multiple
      sclerosis exacerbation recovery, treatment patterns and safety outcomes in patients with
      multiple sclerosis experiencing exacerbations treated with H.P. Acthar® Gel (Acthar Gel) in
      standard practice in the United States.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Multiple Sclerosis Impact Scale version 1 (MSIS-29v1)</measure>
    <time_frame>6 months post exacerbation</time_frame>
    <description>Evaluates the physical and psychological impact of MS</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H.P. Acthar® Gel (repository corticotropin injection)</intervention_name>
    <other_name>Acthar</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with a relapsing form of MS who initiate treatment with Acthar Gel for an
        MS exacerbation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female ≥ 18 years of age.

          2. Patient has a clinically definite relapsing form of Multiple Sclerosis according to
             McDonald Criteria (2010 revision).

          3. Patient with an acute MS exacerbation as determined by their treating clinician.

          4. Patient planning to initiate Acthar Gel for the treatment of an acute MS
             exacerbation.

          5. Patient capable of providing informed consent.

        Exclusion Criteria:

          1. Patients with a diagnosis of Progressive MS.

          2. Patients that require concomitant corticosteroid therapy.

          3. Patients receiving experimental drug therapy.

          4. Patients with a history of scleroderma, systemic fungal infections, ocular herpes
             simplex, or cancer within prior 5 years.

          5. Patients who had recent surgery or have a history of or the presence of a peptic
             ulcer within 6 months prior to study entry, congestive heart failure, or sensitivity
             to proteins of porcine origin.

          6. If female, pregnant or breast-feeding; or, if of childbearing age, an unwillingness
             to use appropriate birth control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elizabeth Donahue</last_name>
    <phone>617-792-5389</phone>
    <email>Elizabeth.Donahue@ubc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bryan Due, PhD</last_name>
    <phone>443-372-8986</phone>
    <email>Bryan.Due@mallinckrodt.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bala Cynwood</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 9, 2016</lastchanged_date>
  <firstreceived_date>December 15, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
